Cellenkos, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cellenkosinc.com
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Regulatory T Cells for Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Excipient
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Cellenkos, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT05695521
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Cellenkos, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05423691
- Locations
- 🇺🇸
UC Davis Health, Sacramento, California, United States
🇺🇸Montefiore Einstein Cancer Center, Bronx, New York, United States
🇺🇸Columbia University, New York, New York, United States
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
- Conditions
- ARDSCOVID19
- Interventions
- Biological: CK0802Drug: Placebo
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Cellenkos, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04468971
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)
- Conditions
- Guillain-Barré Syndrome
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Cellenkos, Inc.
- Registration Number
- NCT03773328
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Cellenkos, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03773393
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Cancer Center of Southern California, Santa Monica, California, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States